Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

Tiziana Life Sciences (TLSA) completed patient visits in its Phase 2a trial for intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial enrolled 48 patients and aims to evaluate safety, tolerability, and efficacy. The company expects to announce topline data in October. Foralumab is Tiziana's lead development candidate.

Tiziana Life Sciences (TLSA) partnered with KAIMRC and the Foundation for Neurologic Diseases to study foralumab in combination with anti-CD20 therapy for RRMS patients. Foralumab has shown reductions in neuroinflammation in prior studies. The trial targets patients who respond poorly to anti-CD20 therapy alone. Tiziana's CEO signed the agreement at the Riyadh Global Medical Biotechnology Summit. Shares rose over 18% on the news.

Tiziana Life Sciences (TLSA) signed an MOU with KAIMRC and others to advance trials of intranasal foralumab for relapsing-remitting multiple sclerosis (RRMS). The collaboration aims to evaluate foralumab's combination with anti-CD20 therapy. TLSA's stock rose 14.27% in pre-market trading. The company's stock has traded between $0.76 and $2.35 over the past year.

Tiziana Life Sciences (TLSA) shares rose 15.6% premarket after announcing a partnership with King Abdullah International Medical Research Center for a multiple sclerosis clinical trial. The trial will evaluate intranasal foralumab combined with anti-CD20 therapy in RRMS patients. CEO Ivor Elrifi noted this expands their MS research beyond the ongoing Phase 2 trial for na-SPMS, with results expected in October.

Tiziana Life Sciences (TLSA) announced a clinical trial collaboration to test intranasal foralumab with anti-CD20 therapy for RRMS patients. The company has no revenue, a GF Score of 23/100, and $1.0M in insider purchases over 12 months. TLSA's market cap is approximately $103M.

Tiziana Life Sciences (TLSA) signed an MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on a clinical trial. The trial will evaluate intranasal foralumab combined with anti-CD20 therapy in RRMS patients who respond poorly to anti-CD20 alone. Foralumab has shown promise in reducing neuroinflammation in prior studies.